Twist Bioscience (TWST)
Nasdaq Market Closed
Twist Bioscience Corporation is a synthetic biology company focused on making DNA synthesis faster, more scalable, and more accessible to researchers and commercial customers. The company’s core technology uses a silicon-based manufacturing platform to write synthetic DNA at high throughput, replacing older approaches that rely on larger reaction volumes and plastic well plates. By miniaturising and parallelising the synthesis process, Twist aims to lower costs, improve consistency, and support the growing demand for engineered biological materials.
The company sells a broad range of products built around synthetic DNA, including genes, oligonucleotide pools, variant libraries, and next-generation sequencing sample preparation tools. Its products are used by customers in academic research, biotechnology, pharmaceutical development, agriculture, industrial biology, and diagnostics. Twist’s platform is particularly relevant in fields where researchers need many DNA sequences quickly, such as antibody discovery, protein engineering, CRISPR-based research, and the design of biological pathways.
Twist also participates in applied markets that extend beyond basic research. Its capabilities support biologics discovery through synthetic antibody libraries and related screening tools, and the company has explored DNA as a medium for digital data storage, a long-term opportunity based on DNA’s density and durability. Revenue is generated across the Americas, Europe, the Middle East and Africa, and Asia-Pacific, with the Americas representing the largest contribution. For investors, Twist Bioscience is a life sciences tools company tied to the expanding use of synthetic biology, where scale, accuracy, turnaround time, and platform breadth are central competitive factors.
Last updated
- Market Cap
- 4.37B
- P/E
- —
- P/FCF
- —
- P/S
- 10.67
- Enterprise Value
- 4.26B
- Sector
- Health Care
- Industry
- Biological Products, Except Diagnostic Substances
- Address
- 681 GATEWAY BLVD., SOUTH SAN FRANCISCO, CA, 94080
DNA Computing Market - Global Forecast 2025-2032
Cell Culture Microcarriers Market Size Leads at 8.54% CAGR by 2034 – Towards Healthcare
DNA Data Storage Market to Reach $3348 Million by 2030, Transforming the Future of Data Archiving
Global Antibody Discovery Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
U.S. Minimal Residual Disease Testing Market Trends Analysis Report 2025-2033 | Integration with Personalized Medicines, & Rising Incidence and Prevalence of Hematological Malignancies Fueling Growth
Antibody Discovery Market Size to Achieve USD 22,570 Mn by 2034 | Statifacts
RNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR Report
Gene Panel Market to Surpass USD 11.75 Billion by 2031 | SkyQuest Technology
DNA Synthesis Market to Reach USD 15.48 Billion by 2032 Driven by Demand for Genomics Research and Personalized Medicine
DNA Synthesis Market Analysis and Forecast, 2024-2028 - Rising Investments in Genomics R&D and Advances in Sequencing Technologies Driving the Industry at 18.1% CAGR
Synthetic Biology market is projected to grow at a CAGR of 25.4% by 2034: Visiongain - GlobeNewswire
Are Medical Stocks Lagging Bicycle Therapeutics (BCYC) This Year?
Amgen's (AMGN) Blincyto Gets FDA Nod for Consolidation Treatment
Is DaVita (DVA) Stock Outpacing Its Medical Peers This Year?
What Makes Twist Bioscience (TWST) a Strong Momentum Stock: Buy Now?
Twist Bioscience (TWST) Reports Q2 Loss, Tops Revenue Estimates
Twist Bioscience (TWST) Soars 12.5%: Is Further Upside Left in the Stock?
5 Best Performing Stocks of the Top ETF of November
Twist Bioscience (TWST) Reports Q4 Loss, Tops Revenue Estimates
Blueprint Medicines (BPMC) Reports Q3 Loss, Tops Revenue Estimates
- Market Cap
Market cap is the total value of a company's shares, calculated by multiplying the stock price by the number of shares outstanding.
- 4.37B
- Enterprise Value
Enterprise value is the total value of a company, including its market cap, debt, and cash.
- 4.26B
- P/E
P/E ratio compares a company's share price to its earnings per share.
- —
- P/B
P/B ratio compares a company's share price to its book value per share.
- 9.6
- P/S
P/S ratio compares a company's share price to its revenue per share.
- 10.67
- EV / EBITDA
EV/EBITDA measures a company's value compared to its earnings before interest, taxes, depreciation, and amortization.
- -39.84
- EV / Sales
EV/Sales measures a company's value compared to its total revenue.
- 10.41
- EPS
- -1.31
- Dividend Yield
Dividend yield shows how much a company pays in dividends each year compared to its share price.
- 0%
- P/FCF
Price-to-free-cash-flow ratio compares a company's share price to the cash it generates after expenses and investments.
- —
- P/CF
P/CF ratio compares a company's share price to the cash flow it generates from its operations.
- —
- Free Cash Flow
Free cash flow is the cash a company has left after covering operating costs and capital expenses.
- -100.04M
- ROE
ROE measures how effectively a company uses shareholders' equity to generate profit.
- -17.86%
- ROA
ROA measures how effectively a company uses its assets to generate profit.
- -12.02%
- Debt / Equity
Debt-to-equity ratio compares a company's total debt to its shareholders' equity.
- 0.03
- Current Ratio
Current ratio measures a company's ability to pay short-term debts using its short-term assets.
- 2.7
- Quick Ratio
Quick ratio measures a company's ability to pay short-term debts using cash and other easily available assets.
- 2.42
- Cash
Cash ratio measures a company's ability to cover short-term debts using only cash and cash equivalents.
- 1.02
- Avg Volume
Average volume shows the average number of shares traded over the last 30 trading days, helping indicate liquidity.
- 1.54M
- Fundamentals Snapshot Price
Fundamentals snapshot price is the stock price used when calculating the company's financial ratios and metrics.
- 70.15
Income Statement
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Revenue | 110.72M | 103.7M | 99.01M | 96.06M | 92.79M |
| Gross profit | 57.12M | 53.97M | 50.84M | 51.3M | 46.03M |
| Operating income | -45.86M | -32.9M | -29.93M | -30.12M | -41.56M |
| EBITDA | -32.24M | -26.71M | -23.93M | -24.06M | -35.16M |
| Net income | -44.02M | -30.51M | -27.14M | 20.39M | -39.33M |
| Basic EPS | -0.71 | -0.5 | -0.45 | 0.34 | -0.66 |
| Diluted EPS | -0.71 | -0.5 | -0.45 | 0.33 | -0.66 |
Balance Sheet
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Total assets | 676.21M | 638.09M | 641.86M | 643.61M | 595.62M |
| Total liabilities | 221.12M | 181.99M | 168.9M | 165.41M | 155.51M |
| Total equity | 455.09M | 456.1M | 472.96M | 478.2M | 440.11M |
| Cash & equivalents | 122.67M | 148.59M | 183.05M | 201.37M | 210.44M |
| Current assets | 323.44M | 303.88M | 332.97M | 339.78M | 338.44M |
| Current liabilities | 119.98M | 80.44M | 91.41M | 87.07M | 74.98M |
Cash Flow
| Line Item | 2026 Q2 | 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 |
|---|---|---|---|---|---|
| Operating cash flow | -17.56M | -24.81M | -11.81M | -1.4M | -12.99M |
| Investing cash flow | -12.71M | -9.93M | -12.4M | -9.4M | -1.43M |
| Financing cash flow | 4.14M | 298K | 5.57M | 1.83M | 3.2M |
| Change in cash | -26.13M | -34.44M | -18.48M | -9.04M | -11.11M |
| Kind | Filing | Date | Link |
|---|---|---|---|
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| form 4 | Form 4 — JOHANNESSEN JAN | View Filing | |
| form 4 | Form 4 — JOHANNESSEN JAN | View Filing | |
| form 4 | Form 4 — JOHANNESSEN JAN | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| form 4 | Form 4 — WERNER ROBERT F. | View Filing | |
| edgar index | SCHEDULE 13G/A — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 8-K — Twist Bioscience Corp | View Filing | |
| edgar index | 10-Q — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| eight k text | 8-K — 8-K | View Filing | |
| form 4 | Form 4 — WERNER ROBERT F. | View Filing | |
| form 4 | Form 4 — Green Paula | View Filing | |
| form 4 | Form 4 — Finn Patrick John | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Cho Dennis | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| form 4 | Form 4 — Starovasnik Melissa A. | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| form 4 | Form 4 — Finn Patrick John | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| edgar index | 4 — Twist Bioscience Corp | View Filing | |
| edgar index | 144 — Twist Bioscience Corp | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing | |
| form 4 | Form 4 — Leproust Emily M. | View Filing |